Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody.
Few patients with Behçet's syndrome have gastrointestinal ulceration. Such patients are difficult to treat and have a higher mortality. Faced with refractory symptoms in two patients with intestinal Behçet's, we used the tumour necrosis factor alpha (TNF-alpha) monoclonal antibody inflixim...
Autors principals: | Travis, S, Czajkowski, M, McGovern, D, Watson, R, Bell, A |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
2001
|
Ítems similars
-
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
per: Elliot, M, et al.
Publicat: (2008) -
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
per: Elliott, M, et al.
Publicat: (1993) -
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
per: Elliott, M, et al.
Publicat: (1994) -
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
per: Jihye Park, et al.
Publicat: (2018-11-01) -
What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
per: Feldmann, M
Publicat: (1996)